Coronary CT angiography proved the effectiveness of a therapy for patients who experience acute coronary syndrome (ACS), according to research published in JACC: Cardiovascular Imaging.
The study, published online Oct. 18, showed how low-dose colchicine therapy can favorably remodel coronary plaque, a prominent predictor of future cardiovascular events, after ACS.
“Our findings suggest, for the first time, that low-dose colchicine therapy favorably modifies coronary plaque, independent of high-dose statin intensification therapy and substantial low-density lipoprotein reduction,” wrote Kaivan Vaidya, MBBS, with the department of cardiology at Royal Prince Alfred Hospital in Sydney, and colleagues. “The improvements in plaque morphology are likely driven by the anti-inflammatory properties of colchicine, as demonstrated by reductions in hsCRP, rather than changes in lipoproteins. Colchicine may be beneficial as an additional secondary prevention agent in patients post-ACS if validated in future studies.”
See the full story at CardiovascularBusiness.com:
Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.